Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2024-07-22 00:00:00 ET · period of report 2024-07-18 · accession 0001415889-24-019905 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-07-22 | 2024-07-22 | ARTV | Aslan Fred | Pres, CEO, Dir | A - Grant | $0.00 | +228.9K | 228.9K | New | $0 |
| D | 2024-07-22 | 2024-07-18 | ARTV | Aslan Fred | Pres, CEO, Dir | A - Grant | $0.00 | +343.8K | 343.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-22 | A | A | 228,905 | $0.00 | 228,905 | D | — | — | (F1) Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. |
| 2 | Derivative | Employee Stock Option (Right to Buy) | 2024-07-18 | A | A | 343,811 | $0.00 | 343,811 | D | $12.00 · — to 2034-07-17 | 343,811 Common Stock | (F2) 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. |